Utility of platelet function analyzer as a screening tool for the diagnosis of Von Willebrand disease in adolescents with menorrhagia

2013 ◽  
Vol 60 (7) ◽  
pp. 1184-1187 ◽  
Author(s):  
Swati Naik ◽  
Jun Teruya ◽  
Jennifer E. Dietrich ◽  
Purvi Jariwala ◽  
Esther Soundar ◽  
...  
Keyword(s):  
Platelet Function ◽  
Screening Tool ◽  
Von Willebrand Disease ◽  
Function Analyzer ◽  
Platelet Function Analyzer ◽  
Von Willebrand

Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia

2004 ◽  
Vol 191 (2) ◽  
pp. 449-455 ◽  
Author(s):  
Andra H. James ◽  
Andrea S. Lukes ◽  
Leo R. Brancazio ◽  
Elizabeth Thames ◽  
Thomas L. Ortel
Keyword(s):  
Platelet Function ◽  
Von Willebrand Disease ◽  
Function Analyzer ◽  
Platelet Function Analyzer ◽  
Von Willebrand

Acquired Disorders of Platelet Function

Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 403-408 ◽  
Author(s):  
Amy A. Hassan ◽  
Michael H. Kroll
Keyword(s):  
Platelet Function ◽  
Hepatic Cirrhosis ◽  
Treatment Options ◽  
Underlying Disease ◽  
Von Willebrand Disease ◽  
Platelet Aggregometry ◽  
Platelet Disorder ◽  
Function Analyzer ◽  
Platelet Function Analyzer ◽  
Von Willebrand

Abstract A qualitative abnormality of platelet function should be considered in patients with mucocutaneous bleeding in the absence of thrombocytopenia or von Willebrand disease. Antiplatelet drugs are the most common cause of acquired platelet disorders leading to bleeding. Uremia, hepatic cirrhosis, myeloma and related disorders, polycythemia vera, essential thrombocythemia, and cardiopulmonary bypass have long been recognized as clinical situations in which platelet dysfunction may contribute to bleeding. When an acquired platelet disorder is suspected, it is useful to examine platelet function by measuring the bleeding time, examining platelet-dependent closure time in a platelet function analyzer and performing platelet aggregometry. When a specific acquired platelet disorder is diagnosed, many treatment options are available including controlling the underlying disease, giving platelet transfusions and administering a hemostatic drug.

Description of an In Vitro Platelet Function Analyzer-PFA-100™

1995 ◽  
Vol 21 (S 02) ◽  
pp. 106-112 ◽  
Author(s):  
Sourav Kundu ◽  
Eric Heilmann ◽  
Reynaldo Sio ◽  
Carmen Garcia ◽  
Rosa Davidson ◽  
...  
Keyword(s):  
Platelet Function ◽  
Quantitative Measure ◽  
Biologically Active ◽  
High Shear Rates ◽  
Function Analyzer ◽  
Potential Applications ◽  
Time Required ◽  
Platelet Function Analyzer ◽  
Von Willebrand

A new in vitro system for the detection of platelet dysfunction, PFA-100™* has been developed. It provides a quantitative measure of platelet function in anticoagulated whole blood. The system comprises a microprocessor-controlled instrument and a disposable test cartridge containing a biologically active membrane. The instrument aspirates a blood sample under constant vacuum from the sample reservoir through a capillary and a microscopic aperture cut into the membrane. The membrane is coated with collagen and epinephrine or adenosine 5’-diphosphate. The presence of these biochemical stimuli, and the high shear rates generated under the standardized flow conditions, result in platelet attachment, activation, and aggregation, slowly building a stable platelet plug at the aperture. The time required to obtain full occlusion of the aperture is reported as the m“closure time.” We have found that impairment of von Willebrand factor, or inhibition of platelet receptors glycoprotein Ib or IIblIIIa with monoclonal antibodies or peptides, resulted in abnormal closure times. An antifibrinogen antibody, in contrast, failed to show any effect. The test appears to be sensitive to platelet adherence and aggregation abnormalities. The PFA-100™ system has potential applications in routine evaluation of platelet function in the clinical setting because of its accuracy, ease of operation, and rapid turnaround of results. * Under evaluation

Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease

2009 ◽  
Vol 101 (01) ◽  
pp. 123-133 ◽  
Author(s):  
Shirley Williams ◽  
Diane Nugent ◽  
Paul Harrison ◽  
Helen Segal ◽  
Anila Syed ◽  
...  
Keyword(s):  
Candidate Genes ◽  
Platelet Function ◽  
Purinergic Receptor ◽  
Blood Platelet ◽  
Function Analyzer ◽  
Prostaglandin H ◽  
Ischemic Attack ◽  
Platelet Function Analyzer ◽  
Von Willebrand ◽  
Willebrand Factor

SummaryWe studied the effect of prophylactic aspirin (ASA) ingestion on platelet function in 463 patients with stroke, transient ischemic attack (TIA) or acute coronary disease (ACD), using the Platelet Function Analyzer-100 (PFA-100). We correlated ASA responsiveness with haplotypes of seven candidate genes, selected for their documented role in platelet function, namely, the genes for integrins α2β1and αIIbβ3 (ITGA2, ITGA2B, and ITGB3), platelet glycoproteins Ibα and VI (GPIBA and GP6), the purinergic receptor P2Y1 (P2RY1), and prostaglandin H synthase 1 (PTGS1 = COX1). Non-responsiveness to ASA was defined as the failure of prior ASA ingestion to prolong the PFA-100 closure time (CT) when blood was perfused through cartridges coated with collagen plus epinephrine (CEPI-CT). ASA non-responsiveness was observed in 114 of 463 patients (24.6 %), but was not associated with haplotypes of any of the seven candidate genes. There was also no association between any haplotypes and the CT when blood was perfused through cartridges coated with collagen plus ADP (CADP-CT). The ASA non-responsive cohort had significantly increased whole blood platelet counts (p = 0.03) and plasma von Willebrand Factor antigen levels (p<0.001), which likely contributes to resistance to the inhibitory effects of ASA in the PFA-100.

Platelet function in cats with hyperthyroidism

2020 ◽  
Vol 22 (12) ◽  
pp. 1214-1218
Author(s):  
Elizabeth C Hiebert ◽  
David L Panciera ◽  
Katie M Boes ◽  
Lara Bartl
Keyword(s):  
Platelet Count ◽  
Platelet Function ◽  
Adenosine Diphosphate ◽  
Control Group ◽  
Closure Time ◽  
Function Analyzer ◽  
The Mean ◽  
Platelet Function Analyzer ◽  
Von Willebrand ◽  
Willebrand Factor

Objectives Cats with hyperthyroidism have been reported to develop thromboembolism, with and without echocardiographic abnormalities consistent with hyperthyroidism. The objective of this study was to compare platelet function in cats with hyperthyroidism with euthyroid age-matched cats. We hypothesized that cats with hyperthyroidism have shortened collagen and adenosine diphosphate (C-ADP) closure times as measured with the platelet function analyzer (PFA-100) in comparison with healthy, age-matched controls. Methods Sixteen hyperthyroid and nine euthyroid healthy cats >7 years of age were recruited from the hospital population. Platelet function, measured using the C-ADP closure times by the PFA-100, and platelet count were measured in healthy euthyroid cats and cats with hyperthyroidism. Results Mean ± SD closure times were not significantly different between control (66.3 ± 9.6 s) and hyperthyroid cats (65.9 ± 11.5 s; P = 0.75). The mean ± SD closure times of hyperthyroid cats that either were untreated or received methimazole for ⩽3 weeks (n = 6; mean 68.5 ± 15.4 s) was not different than that of cats treated for >3 weeks (n = 10; mean 64.3 ± 8.9 s; P = 0.57). The mean automated platelet count was higher in the hyperthyroid group than in the control group ( P = 0.023). Conclusions and relevance Platelet function, as measured by closure time under high shear conditions using C-ADP as an agonist, was not affected by hyperthyroidism in this group of cats. Further research is needed to determine if a hypercoagulable state exists in hyperthyroid cats and the potential roles platelets and von Willebrand factor may have.

scholarly journals The Platelet Function Analyzer (PFA-100) as a Screening Tool in Neurosurgery

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Ralf Karger ◽  
Karoline Reuter ◽  
Jochen Rohlfs ◽  
Christopher Nimsky ◽  
Ulrich Sure ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Platelet Function ◽  
Prophylactic Treatment ◽  
Screening Tool ◽  
Bleeding Complications ◽  
Preoperative Screening ◽  
Perioperative Bleeding ◽  
Neurosurgical Patients ◽  
Function Analyzer ◽  
Platelet Function Analyzer

We investigated whether the inclusion of the PFA-100 in the preoperative screening of neurosurgical patients might reduce perioperative bleeding complications. Patients with intracranial space-occupying lesions who were scheduled for neurosurgery underwent routine preoperative PFA-100 testing. In case of an abnormal PFA test, patients received prophylactic treatment with desmopressin. 93 consecutive patients were compared to 102 consecutive patients with comparable characteristics operated before introduction of the PFA-100 testing. 2 patients (2.2%) in the PFA group and 2 patients (2.0%) in the non-PFA group experienced clinically relevant intracranial bleeding confirmed by computed tomography (OR 1.05, 95% CI 0.39–2.82; ). Transfusions were not significantly different between the two groups. 13 (14.0%) patients in the PFA group and 5 (4.9%) patients in the non-PFA group received desmopressin (OR 3.2, 95% CI 1.1–9.2; ). Preoperative screening with the PFA-100 did result in a significant increase in the administration of desmopressin, which could not reduce perioperative bleeding complications or transfusions.

Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer

Platelets ◽  
2018 ◽  
Vol 30 (2) ◽  
pp. 264-270 ◽  
Author(s):  
Isabell Pekrul ◽  
Thorsten Kragh ◽  
Peter L Turecek ◽  
Aaron R Novack ◽  
Helmut W Ott ◽  
...  
Keyword(s):  
Platelet Function ◽  
Von Willebrand Factor ◽  
Function Analyzer ◽  
Specific Assessment ◽  
Platelet Function Analyzer ◽  
Von Willebrand ◽  
Willebrand Factor
Sign in / Sign up

Export Citation Format

Share Document